Tag Archives: QIAGEN

QIAGEN Expands QIAstat-Dx Operations with New Innovation Hub in Barcelona

(IN BRIEF) QIAGEN is investing in a new innovation hub in Esplugues de Llobregat, Barcelona, to enhance its QIAstat-Dx syndromic testing platform. Opening in 2026, the 8,000-square-meter site will house operations across research, manufacturing, and regulatory functions, focusing on advancing … Read the full press release

FDA Clears QIAGEN’s Rapid QIAstat-Dx Panel for Meningitis and Encephalitis Diagnosis, Expanding Syndromic Test Portfolio

(IN BRIEF) QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel has received FDA clearance, enabling faster and more accurate diagnosis of critical CNS infections like meningitis and encephalitis. This panel, the fourth QIAstat-Dx test approved in the U.S. in 2024, uses real-time PCR to … Read the full press release

QIAGEN Gains FDA Approval for QIAstat-Dx Mini Panel, Enhancing Outpatient Respiratory Diagnostics with Rapid Results

(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release

QIAGEN and Neo4j Strengthen Partnership to Revolutionize Biomedical Data Analysis in Biopharma Industry

(IN BRIEF) QIAGEN Digital Insights has announced an expanded partnership with Neo4j, aiming to enhance biomedical data analysis for the biopharmaceutical industry. This collaboration will integrate Neo4j’s graph database and machine learning capabilities with QIAGEN’s extensive biomedical knowledge base. By … Read the full press release

QIAGEN Launches Enhanced QCI Interpret for High-Throughput NGS Labs

(IN BRIEF) QIAGEN has launched an upgraded version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), tailored for high-throughput next-generation sequencing (NGS) labs. The new release enhances performance metrics like turnaround time and diagnostic yield through … Read the full press release

QIAGEN Expands Presence in Middle East with New Riyadh HQ, MoU with Saudi Ministry of Health, and Oman TB Screening Initiative

(IN BRIEF) QIAGEN, a leading provider of molecular diagnostics and life sciences solutions, is significantly expanding its operations in the Middle East region. In early 2024, the company will open its regional headquarters in Riyadh, Saudi Arabia, to strengthen its … Read the full press release

QIAGEN to Host Global TB Summit 2023: Advancing Tuberculosis Awareness and Action

(IN BRIEF) QIAGEN is organizing the Global TB Clinical and Educational Summit 2023, running from October 17-19, with the theme “Tackling TB together: From awareness to action.” This summit highlights QIAGEN’s dedication to combat tuberculosis (TB) and address the gap … Read the full press release

QIAGEN Advances NGS Efficiency with QIAseq Normalizer Kits for DNA Library Optimization

(IN BRIEF) QIAGEN has launched the QIAseq Normalizer Kits, a new solution for researchers to efficiently pool different DNA libraries for optimal results in next-generation sequencing (NGS) runs. The kit accelerates the process of normalizing DNA concentrations across libraries, reducing … Read the full press release

QIAGEN and Servier Collaborate to Develop Diagnostic Test for Hard-to-Treat Blood Cancer

(IN BRIEF) QIAGEN has entered into a partnership with global pharmaceutical group, Servier, to develop a companion diagnostic test for TIBSOVO, an isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat acute myeloid leukemia (AML). QIAGEN will develop and validate a real-time … Read the full press release

The leading provider of molecular Sample to Insight solutions QIAGEN announces a major expansion of its digital PCR (dPCR) assay offerings

13 new kits and assays allow for quantification of AAV viral titer and residual host cell DNA in cell and gene therapy Custom assay design provides dPCR users with access to tailored multiplex assays for use beyond biopharma applications Milestone … Read the full press release

Le principal fournisseur de solutions moléculaires Sample to Insight QIAGEN annonce une expansion majeure de ses offres de tests PCR numériques (dPCR)

13 nouveaux kits et tests permettent de quantifier le titre viral d’AAV et l’ADN résiduel de la cellule hôte en thérapie cellulaire et génique La conception de tests personnalisés permet aux utilisateurs de dPCR d’accéder à des tests multiplex personnalisés … Read the full press release

QIAGEN, der führende Anbieter von molekularen Sample-to-Insight-Lösungen, kündigt eine bedeutende Erweiterung seines Angebots an digitalen PCR (dPCR)-Assays an

13 neue Kits und Tests ermöglichen die Quantifizierung von AAV-Titern und restlicher Wirtszell-DNA in der Zell- und Gentherapie Custom Assay Design Service bietet Nutzern von dPCR Zugang zu maßgeschneiderten Multiplex-Assays über den Einsatz in Biopharma-Anwendungen hinaus Meilenstein mit mehr als … Read the full press release

QIAGEN gibt neue Meilensteine für seinen Tuberkulose-Test QuantiFERON bekannt

HILDEN, Deutschland, GERMANTOWN, Maryland (USA), und SHANGHAI, China, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA), ein deutscher Anbieter von Sample-to-Insights-Lösungen, die es Kunden ermöglichen, Einblicke in die Bausteine des Lebens – DNA, RNA und Proteine … Read the full press release

QIAGEN annonce de nouvelles étapes pour son test de tuberculose QuantiFERON

(COMMUNIQUÉ DE PRESSE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN NV (NYSE : QGEN ; Frankfurt Prime Standard : QIA), une société allemande fournisseur de solutions Sample to Insights qui permettent aux clients de débloquer des informations sur … Read the full press release

QIAGEN announces new milestones for its QuantiFERON tuberculosis test

(PRESS RELEASE) HILDEN, Germany / GERMANTOWN, MD, United Staes / SHANGHAI, 7-Feb-2022 — /EuropaWire/ — QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a German provider of Sample to Insights solutions that enable customers to unlock insights from the building … Read the full press release

QIAGEN announces two new collaborations for its dPCR platform QIAcuity: Atila BioSystems and Actome

Expanding range of applications for growing base of QIAcuity digital PCR instruments Two new collaborations: Atila BioSystems expands menu to non-invasive prenatal testing (NIPT), while Actome partnership designed to enable for the first time protein analysis using digital PCR technology … Read the full press release

QIAGEN appoints Dr. Toralf Haag as a member of the Supervisory Board and the Audit Committee

(PRESS RELEASE) VENLO, the Netherlands, 8-Jan-2021 — /EuropaWire/ — QIAGEN announces the appointment of Dr. Toralf Haag as a member of the Supervisory Board with immediate effect. He will also become a member of the Audit Committee. Dr. Haag was … Read the full press release

QIAGEN Ergebnisse einer neuen Evaluierung im Bereich der Frauengesundheit die hohe Genauigkeit seiner Bioinformatik-Lösungen untermauern

Ergebnisse der Evaluierung der QCI-Plattform zur Interpretation klinisch relevanter Genvarianten werden auf der ASHG 2017 von Counsyl vorgestellt Orlando, Florida (USA), Germantown, Maryland (USA), und Hilden (Deutschland), 20-Oct-2017 — /EuropaWire/ — QIAGEN (NASDAQ: QGEN; Frankfurter Börse: QIA) gab heute bekannt, … Read the full press release

France’s Ministry of Health and Social Affairs approves reimbursement for QIAGEN’s QuantiFERON-TB® Gold Plus latent tuberculosis test

Gold-standard test for latent tuberculosis infection will be covered by national health insurance Hilden, Germany, and Paris, France, 23-Jun-2017 — /EuropaWire/ — QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that France’s Ministry of Health and Social Affairs … Read the full press release

DiaSorin, QIAGEN to develop new tests for DiaSorin’s LIAISON family of analyzers

Saluggia, Italy; Hilden, Germany, and Germantown, Maryland, USA, 23-Jun-2017 — /EuropaWire/ — DiaSorin (FTSE Italy Mid Cap: DIA) and QIAGEN (NASDAQ: QGEN; Frankfurt Stock Exchange: QIA) announced today a new collaboration to develop new tests for DiaSorin’s LIAISON family of … Read the full press release